Predictive Oncology Inc. (NASDAQ:POAI) shares surged after announcing the expansion of its AI-driven drug discovery platform to include novel biomarker discovery. This initiative follows successful results from an ovarian cancer study, which demonstrated the platform's ability to predict survival outcomes more accurately than clinical data alone. The stock has risen 63% over the past month but is still down 50.57% over the past year.